- Login
- Manage Portfolio
- Post a StockTalk
- Write an Instablog
- Get Daily Email Alert
-
Seeking Alpha
-
Arena Pharmaceuticals: Near Term Gamble May Be Worth It
-
A Biotech Triple Play: Dendreon, BioCryst and Arena
-
Arena Pharma Could Be on the Verge of Collapse
-
Wall Street Breakfast: Must-Know News
-
Investing in the Obesity Drug Basket
-
Arena, The Aftermath
-
Two Positive Notes for Arena Pharmaceuticals
-
Arena's Obesity Drug Not Likely to Make It
-
Vivus: A One Trick Pony
-
Orexigen's Contrave: Generic Would Be No Cheaper
-
Arena's Financing Deal with Azimuth Is a Healthy Move
-
Four Weighty Reasons to Invest in Vivus
-
Don't Expect Amylin to Eat the Obesity Market's Lunch
-
Vivus: Obesity Experimental Drug Has Promising Outlook
-
Pending Clinical Trial Results: Ten Extreme Trades
-
Arena's New Obesity Drug: Safe, But Not Too Efficacious
-
Safety Data on Arena's Weight Loss Drug Could Pave Way for Good Partnership
-
Wall Street Breakfast: Must-Know News
-
9 Possible Pharma Deals for 2009
-
Biotech Update: Arena Pharmaceuticals, Acusphere, Cephalon, ViroPharma, Auxilium
-
Why Orexigen's Empatic News Is Good
-
Q1 2009 Biotech Roundup: The Good, the Bad and the Ugly
-
Arena's Prospects Will Be in the Eye of the Suitors
-
Know Your Options When Investing in Biotech Stocks
-
Arena’s Lorcaserin Has Safety Edge
-
Arena's Edge in the Obesity Drug Race
-
Three Ways to Play Arena Pharmaceuticals
-
Cramer Likes Orexigen: Should You?
-
Vivus: A Bet on Well-Funded, Late-Stage Pipeline
-
BioMed News Bytes: Arena, ImmunoCellular, YM Bio